Environmental, Social And Governance Report

Overview

The report is Grand Pharma's first standalone ESG report. It describes an annual double materiality assessment and Board approval of the 2023 materiality matrix. Reported performance includes 10,534 total employees and 378,534.39 tCO2e of Scope 1 and 2 GHG emissions, alongside a 10% GHG emission-intensity reduction target by 2030 from a 2023 base.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services